WEBULL
News
LNTH
63.30
+2.31%
1.43
3 of Wall Street’s Favorite Stocks to Keep an Eye On
Barchart · 2d ago
Weekly Report: what happened at LNTH last week (1124-1128)?
Weekly Report · 6d ago
Jefferies Sticks to Their Buy Rating for Lantheus (LNTH)
TipRanks · 11/24 13:56
Lantheus to Present New Florbetaben F18 Data at CTAD 2025
Reuters · 11/24 13:30
Weekly Report: what happened at LNTH last week (1117-1121)?
Weekly Report · 11/24 09:33
Align Technology, Tandem Diabetes, Integra LifeSciences, Lantheus, and Inspire Medical Systems Shares Skyrocket, What You Need To Know
Barchart · 11/21 17:44
1 Oversold Stock Ready to Bounce Back and 2 We Avoid
Barchart · 11/19 07:04
Weekly Report: what happened at LNTH last week (1110-1114)?
Weekly Report · 11/17 09:34
The Bottom Fishing Club - Lantheus Holdings: Interesting Buy Momentum Supporting Price
Seeking Alpha · 11/13 14:28
Carillon Eagle Small Cap Growth Fund Q3 2025 Portfolio Update
Seeking Alpha · 11/13 06:50
Lantheus CEO Brian Markison Announces Retirement
TipRanks · 11/12 22:10
Lantheus Holdings Sets CEO Retirement Pay and Post-Retirement Advisory Fee
Reuters · 11/12 21:31
LANTHEUS HOLDINGS INC <LNTH.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $90 FROM $97
Reuters · 11/12 13:49
U.S. RESEARCH ROUNDUP-Floor & Decor Holdings, Composecure, Outfront Media
Reuters · 11/12 07:18
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
Barchart · 11/11 15:18
Lantheus Holdings Price Target Cut to $61.00/Share From $63.00 by Truist Securities
Dow Jones · 11/10 17:01
Truist Securities Reiterates Hold on Lantheus Holdings, Lowers Price Target to $61
Benzinga · 11/10 16:51
LANTHEUS HOLDINGS INC <LNTH.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $61 FROM $63
Reuters · 11/10 12:26
LNTH FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit
Barchart · 11/10 10:20
Weekly Report: what happened at LNTH last week (1103-1107)?
Weekly Report · 11/10 09:33
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.